Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices

Ranjana Arora, Richard Press

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-ABL1 RNA levels) is an emerging treatment goal becoming attainable for more patients due to the availability of second-generation TKIs. Deep molecular responses are associated with improved long-term outcomes and are required prior to attempting cessation of treatment in treatment-free remission clinical trials. The National Comprehensive Cancer Network and European LeukemiaNet recommend regular monitoring of BCR-ABL1 RNA levels using real-time quantitative polymerase chain reaction (RQ-PCR). However, BCR-ABL1 RQ-PCR is a complex laboratory-developed test; routine quantitative results from clinical diagnostic laboratories may differ from those used to establish the recommendations. Although an International Scale (IS) was developed for standardized reporting of BCR-ABL1 RNA levels, IS adoption has been slow in the United States, but is now used by the vast majority of laboratories. Here, we discuss the importance of molecular monitoring in CML, gaps between current and best molecular monitoring practices in the United States, and challenges and potential solutions for universal IS adoption in the United States.

Original languageEnglish (US)
Pages (from-to)8-16
Number of pages9
JournalLeukemia and Lymphoma
Volume58
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Practice Guidelines
RNA
Protein-Tyrosine Kinases
Real-Time Polymerase Chain Reaction
Philadelphia Chromosome
Withholding Treatment
Oncogene Proteins
Therapeutics
Clinical Trials
Neoplasms

Keywords

  • BCR-ABL1
  • deep molecular response
  • International Scale
  • myeloid leukemias and dysplasias
  • real-time quantitative polymerase chain reaction

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Measurement of BCR-ABL1 transcripts on the International Scale in the United States : current status and best practices. / Arora, Ranjana; Press, Richard.

In: Leukemia and Lymphoma, Vol. 58, No. 1, 02.01.2017, p. 8-16.

Research output: Contribution to journalReview article

@article{9ede66ed00bb44369c7a2ce8b08b64c9,
title = "Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices",
abstract = "Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-ABL1 RNA levels) is an emerging treatment goal becoming attainable for more patients due to the availability of second-generation TKIs. Deep molecular responses are associated with improved long-term outcomes and are required prior to attempting cessation of treatment in treatment-free remission clinical trials. The National Comprehensive Cancer Network and European LeukemiaNet recommend regular monitoring of BCR-ABL1 RNA levels using real-time quantitative polymerase chain reaction (RQ-PCR). However, BCR-ABL1 RQ-PCR is a complex laboratory-developed test; routine quantitative results from clinical diagnostic laboratories may differ from those used to establish the recommendations. Although an International Scale (IS) was developed for standardized reporting of BCR-ABL1 RNA levels, IS adoption has been slow in the United States, but is now used by the vast majority of laboratories. Here, we discuss the importance of molecular monitoring in CML, gaps between current and best molecular monitoring practices in the United States, and challenges and potential solutions for universal IS adoption in the United States.",
keywords = "BCR-ABL1, deep molecular response, International Scale, myeloid leukemias and dysplasias, real-time quantitative polymerase chain reaction",
author = "Ranjana Arora and Richard Press",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/10428194.2016.1190974",
language = "English (US)",
volume = "58",
pages = "8--16",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Measurement of BCR-ABL1 transcripts on the International Scale in the United States

T2 - current status and best practices

AU - Arora, Ranjana

AU - Press, Richard

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-ABL1 RNA levels) is an emerging treatment goal becoming attainable for more patients due to the availability of second-generation TKIs. Deep molecular responses are associated with improved long-term outcomes and are required prior to attempting cessation of treatment in treatment-free remission clinical trials. The National Comprehensive Cancer Network and European LeukemiaNet recommend regular monitoring of BCR-ABL1 RNA levels using real-time quantitative polymerase chain reaction (RQ-PCR). However, BCR-ABL1 RQ-PCR is a complex laboratory-developed test; routine quantitative results from clinical diagnostic laboratories may differ from those used to establish the recommendations. Although an International Scale (IS) was developed for standardized reporting of BCR-ABL1 RNA levels, IS adoption has been slow in the United States, but is now used by the vast majority of laboratories. Here, we discuss the importance of molecular monitoring in CML, gaps between current and best molecular monitoring practices in the United States, and challenges and potential solutions for universal IS adoption in the United States.

AB - Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-ABL1 RNA levels) is an emerging treatment goal becoming attainable for more patients due to the availability of second-generation TKIs. Deep molecular responses are associated with improved long-term outcomes and are required prior to attempting cessation of treatment in treatment-free remission clinical trials. The National Comprehensive Cancer Network and European LeukemiaNet recommend regular monitoring of BCR-ABL1 RNA levels using real-time quantitative polymerase chain reaction (RQ-PCR). However, BCR-ABL1 RQ-PCR is a complex laboratory-developed test; routine quantitative results from clinical diagnostic laboratories may differ from those used to establish the recommendations. Although an International Scale (IS) was developed for standardized reporting of BCR-ABL1 RNA levels, IS adoption has been slow in the United States, but is now used by the vast majority of laboratories. Here, we discuss the importance of molecular monitoring in CML, gaps between current and best molecular monitoring practices in the United States, and challenges and potential solutions for universal IS adoption in the United States.

KW - BCR-ABL1

KW - deep molecular response

KW - International Scale

KW - myeloid leukemias and dysplasias

KW - real-time quantitative polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=84994480538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994480538&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1190974

DO - 10.1080/10428194.2016.1190974

M3 - Review article

C2 - 27412040

AN - SCOPUS:84994480538

VL - 58

SP - 8

EP - 16

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -